Not Tagged
Not Tagged
['cspc', 'crpc', 'cspc ']
 the differences in pfs/os benefit between mcspc versus mcrpc is likely representative of the different tumor biology. os data for several nhts continues to mature. os benefit may increase once median os is reached in trials. regardless, continued drug development is warranted.
Physician and researcher with interests in genitourinary cancers and health policy. Tweets are my own views, and are not medical advice.